{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:34:04Z","timestamp":1790732044738,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"National Institutes of Health\/National Cancer Institute Cancer Center","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.bbmt.2017.10.017","type":"journal-article","created":{"date-parts":[[2017,10,14]],"date-time":"2017-10-14T05:15:33Z","timestamp":1507958133000},"page":"27-31","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["Building a Safer and Faster CAR: Seatbelts, Airbags, and CRISPR"],"prefix":"10.1016","volume":"24","author":[{"given":"Miguel-Angel","family":"Perales","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Partow","family":"Kebriaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie S.","family":"Kean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Sadelain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2017.10.017_bib0010","doi-asserted-by":"crossref","first-page":"177ra138","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia","volume":"5","author":"Brentjens","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.bbmt.2017.10.017_bib0015","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias","volume":"118","author":"Brentjens","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.10.017_bib0020","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2017.10.017_bib0025","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1200\/JCO.2014.60.3449","article-title":"Chimeric antigen receptor T cells for cancer immunotherapy","volume":"33","author":"Curran","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2017.10.017_bib0030","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s12185-013-1479-5","article-title":"Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies","volume":"99","author":"Davila","year":"2014","journal-title":"Int J Hematol"},{"key":"10.1016\/j.bbmt.2017.10.017_bib0035","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nrc3565","article-title":"Gene-engineered T cells for cancer therapy","volume":"13","author":"Kershaw","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bbmt.2017.10.017_bib0040","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1182\/blood-2016-02-629063","article-title":"CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date","volume":"127","author":"Park","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.10.017_bib0045","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1182\/blood-2014-12-580068","article-title":"CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"125","author":"Maude","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.10.017_bib0050","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1177\/2040620715588916","article-title":"CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL)","volume":"6","author":"Tasian","year":"2015","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.bbmt.2017.10.017_bib0055","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2017.10.017_bib0060","doi-asserted-by":"crossref","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.bbmt.2017.10.017_bib0065","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2017.10.017_bib0070","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.10.017_bib0075","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2017.10.017_bib0080","doi-asserted-by":"crossref","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.bbmt.2017.10.017_bib0085","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.V128.22.219.219","article-title":"CD19CAR T cell products of defined CD4:CD8 composition and transgene expression show prolonged persistence and durable MRD-negative remission in pediatric and young adult B-cell ALL","volume":"128","author":"Gardner","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.10.017_bib0090","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nature22395","article-title":"Therapeutic T cell engineering","volume":"545","author":"Sadelain","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.bbmt.2017.10.017_bib0095","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1200\/JCO.2017.72.8519","article-title":"Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib","volume":"35","author":"Turtle","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2017.10.017_bib0100","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1097\/CCO.0000000000000408","article-title":"Stop and go: hematopoietic cell transplantation in the era of chimeric antigen receptor T cells and checkpoint inhibitors","volume":"29","author":"Ghosh","year":"2017","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.bbmt.2017.10.017_bib0105","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.10.017_bib0110","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.bbmt.2012.10.021","article-title":"Chimeric antigen receptor-modified T cells: clinical translation in stem cell transplantation and beyond","volume":"19","author":"Riddell","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.10.017_bib0115","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.bbmt.2015.10.014","article-title":"Fast cars and no brakes: autologous stem cell transplantation as a platform for novel immunotherapies","volume":"22","author":"Perales","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.10.017_bib0120","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.bbmt.2016.09.002","article-title":"Chimeric antigen receptor T cells and hematopoietic cell transplantation: how not to put the CART before the horse","volume":"23","author":"Kenderian","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.10.017_bib0125","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2017.10.017_bib0130","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.10.017_bib0135","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/bjh.14475","article-title":"The promise of chimeric antigen receptor T cells (CARTs) in leukaemia","volume":"177","author":"Orlowski","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2017.10.017_bib0140","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.bbmt.2017.10.017_bib0145","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/blood-2016-01-694356","article-title":"Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy","volume":"128","author":"Bhoj","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bbmt.2017.10.017_bib0150","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy\u2014assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.bbmt.2017.10.017_bib0155","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s40425-017-0239-0","article-title":"The why, what, and how of the new FACT standards for immune effector cells","volume":"5","author":"Maus","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.bbmt.2017.10.017_bib0160","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.exphem.2016.07.011","article-title":"Improving the safety of T-cell therapies using an inducible caspase-9 gene","volume":"44","author":"Zhou","year":"2016","journal-title":"Exp Hematol"},{"key":"10.1016\/j.bbmt.2017.10.017_bib0165","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1182\/blood-2011-02-337360","article-title":"A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells","volume":"118","author":"Wang","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.10.017_bib0170","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.1182\/blood-2015-02-628354","article-title":"Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation","volume":"125","author":"Zhou","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.10.017_bib0175","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.10.017_bib0180","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1182\/blood.V128.22.651.651","article-title":"Creation of the first non-human primate model that faithfully recapitulates chimeric antigen receptor (CAR) T cell-mediated cytokine release syndrome (CRS) and neurologic toxicity following B cell-directed CAR-T cell therapy","volume":"128","author":"Taraseviciute","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.10.017_bib0185","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1038\/mt.2012.159","article-title":"High-efficiency transduction of rhesus hematopoietic repopulating cells by a modified HIV1-based lentiviral vector","volume":"20","author":"Uchida","year":"2012","journal-title":"Mol Ther"},{"key":"10.1016\/j.bbmt.2017.10.017_bib0190","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.1182\/blood-2004-01-0045","article-title":"Efficient gene transfer into rhesus repopulating hematopoietic stem cells using a simian immunodeficiency virus-based lentiviral vector system","volume":"103","author":"Hanawa","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.10.017_bib0195","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.ymthe.2017.03.034","article-title":"Chimeric antigen receptors: a cell and gene therapy perspective","volume":"25","author":"Riviere","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.bbmt.2017.10.017_bib0200","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/nrg2842","article-title":"Genome editing with engineered zinc finger nucleases","volume":"11","author":"Urnov","year":"2010","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.bbmt.2017.10.017_bib0205","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrm3486","article-title":"TALENs: a widely applicable technology for targeted genome editing","volume":"14","author":"Joung","year":"2013","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.bbmt.2017.10.017_bib0210","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1146\/annurev-biochem-060713-035418","article-title":"Genome engineering with targetable nucleases","volume":"83","author":"Carroll","year":"2014","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.bbmt.2017.10.017_bib0215","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nbt.2842","article-title":"CRISPR-Cas systems for editing, regulating and targeting genomes","volume":"32","author":"Sander","year":"2014","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.bbmt.2017.10.017_bib0220","doi-asserted-by":"crossref","first-page":"1258096","DOI":"10.1126\/science.1258096","article-title":"Genome editing. The new frontier of genome engineering with CRISPR-Cas9","volume":"346","author":"Doudna","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.bbmt.2017.10.017_bib0225","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.bbmt.2017.10.017_bib0230","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","article-title":"Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells","volume":"28","author":"Zhao","year":"2015","journal-title":"Cancer Cell"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879117307760?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879117307760?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:00:55Z","timestamp":1761058855000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879117307760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S1083879117307760"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2017.10.017","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Building a Safer and Faster CAR: Seatbelts, Airbags, and CRISPR","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2017.10.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 American Society for Blood and Marrow Transplantation.","name":"copyright","label":"Copyright"}]}}